Importer of Controlled Substances Application: Meridian Medical Technologies Inc., 5810-5811 [2018-02647]
Download as PDF
<![CDATA[
5810
Federal Register / Vol. 83, No. 28 / Friday, February 9, 2018 / Notices
Dated: February 2, 2018.
Susan A Gibson,
Deputy Assistant Administrator.
In accordance with 21 CFR
1301.34(a), this is notice that on July 6,
2017, Noramco, Inc., 1550 Olympic
Drive, Athens, Georgia 30601 applied to
be registered as an importer of the
following basic controlled substances:
[FR Doc. 2018–02637 Filed 2–8–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Controlled substance
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Noramco, Inc.
ACTION:
Notice of application.
Registered bulk manufacturer of
the affected basic classes and applicants
therefore, may file written comments on
or objections to the issuance of the
proposed registration on or before
March 12, 2018. Such persons may also
file a written request for a hearing on
the application on or before March 12,
2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
Comments and requests for hearings on
applications to import narcotic raw
material are not appropriate. 72 FR 3417
(January 25, 2007).
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
sradovich on DSK3GMQ082PROD with NOTICES
DATES:
VerDate Sep<11>2014
16:57 Feb 08, 2018
Jkt 244001
Marihuana Extract ........
Marihuana .....................
Tetrahydrocannabinols
Nabilone .......................
Phenylacetone ..............
Thebaine .......................
Opium, raw ...................
Poppy Straw Concentrate.
Tapentadol ....................
Drug
code
Schedule
7350
7360
7370
7379
8501
9333
9600
9670
I
I
I
II
II
II
II
II
9780
II
The company plans to import
phenylacetone (8501), opium, raw
(9600), and poppy straw concentrate
(9670) to bulk manufacture other
controlled substances for distribution to
its customers. The company plans to
import an intermediate form of
tapentadol (9780) to bulk manufacture
tapentadol (9780) for distribution to its
customers. Placement of these drug
codes onto the company’s registration
does not translate into automatic
approval of subsequent permit
applications to import controlled
substances. Approval of permit
applications will occur only when the
registrant’s business activity is
consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization
will not extend to the import of FDA
approved or non-approved finished
dosage forms for commercial sale.
Dated: January 31, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.
[FR Doc. 2018–02646 Filed 2–8–18; 8:45 am]
BILLING CODE 4410–09–P
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on
November 13, 2017, INSYS
Manufacturing LLC, 811 Paloma Drive,
Suite C, Round Rock, TX 78665–2402
applied to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Controlled substance
Marihuana .....................
Tetrahydrocannabinols
Drug
code
7360
7370
Schedule
I
I
The company plans to manufacture
the above listed controlled substances in
bulk for distribution to its customers.
In reference to drug codes 7360
(marihuana), and 7370 (THC), the
company plans to bulk manufacture
these drugs as synthetics. No other
activities for these drug codes are
authorized for this registration.
Dated: January 31, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[FR Doc. 2018–02643 Filed 2–8–18; 8:45 am]
BILLING CODE 4410–09–P
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: INSYS
Manufacturing LLC
ACTION:
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before April 10, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
Drug Enforcement Administration
[Docket No. DEA–392]
Notice of application.
DATES:
DEPARTMENT OF JUSTICE
Importer of Controlled Substances
Application: Meridian Medical
Technologies Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
DATES:
E:\FR\FM\09FEN1.SGM
09FEN1
5811
Federal Register / Vol. 83, No. 28 / Friday, February 9, 2018 / Notices
issuance of the proposed registration on
or before March 12, 2018. Such persons
may also file a written request for a
hearing on the application March 12,
2018.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
Dated: January 31, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.
[FR Doc. 2018–02647 Filed 2–8–18; 8:45 am]
BILLING CODE 4410–09–P
Controlled substance
ADDRESSES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on
December 29, 2017, Meridian Medical
Technologies Inc., 2555 Hermelin Drive,
Saint Louis, Missouri 63144 applied to
be registered as an importer of the
Schedule II control substance for
Morphine (9300) the basic class of
controlled substance.
The company plans to import the
listed controlled substance in finished
dosage form for internal analytical
purposes only. No other activity for this
drug code is authorized for this
registration. Approval of permit
applications will occur only when the
registrant’s business activity is
consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization
will not extend to the import of FDA
approved or non-approved finished
dosage forms for commercial sale.
sradovich on DSK3GMQ082PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
16:57 Feb 08, 2018
Jkt 244001
Nolte Drive, West Deptford, NJ 08066–
1742 applied to be registered as an
importer of the following basic classes
of controlled substances:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Johnson Matthey Inc.
ACTION:
Notice of application.
Registered importers of the
affected basic classes, and applicants
therefore, may file written comments on
or objections to the issuance of the
proposed registration on or before
March 12, 2018. Such persons may also
file a written request for a hearing on
the application on or before March 12,
2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on
November 9, 2017, Johnson Matthey
Inc., Pharmaceutical Materials, 2003
DATES:
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
Coca leaves ..................
Thebaine .......................
Opium, raw ...................
Noroxymorophone ........
Poppy Straw Concentrate.
Fentanyl ........................
Drug
code
Schedule
9040
9333
9600
9668
9670
II
II
II
II
II
9801
II
The company plans to import coca
leaves (9040), raw opium (9600), and
poppy straw concentrate (9670) in order
to bulk manufacture active
pharmaceutical ingredients (API) for
distribution to its customers. The
company plans to also import thebaine
(9333), noroxymorophone (9668), and
fentanyl (9801) to use as analytical
reference standards, both internally and
to be sold to their customers to support
testing of Johnson Matthey Inc.’s API’s
only.
Dated: January 31, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.
[FR Doc. 2018–02639 Filed 2–8–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Mylan Technologies Inc.
ACTION:
Notice of application.
Registered bulk importers of the
affected basic classes, and applicants
therefore, may file written comments on
or objections to the issuance of the
proposed registration on or before
March 12, 2018. Such persons may also
file a written request for a hearing on
the application on or before March 12,
2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
DATES:
E:\FR\FM\09FEN1.SGM
09FEN1
]]>Agencies
[Federal Register Volume 83, Number 28 (Friday, February 9, 2018)]
[Notices]
[Pages 5810-5811]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-02647]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Meridian Medical
Technologies Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
[[Page 5811]]
issuance of the proposed registration on or before March 12, 2018. Such
persons may also file a written request for a hearing on the
application March 12, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on
December 29, 2017, Meridian Medical Technologies Inc., 2555 Hermelin
Drive, Saint Louis, Missouri 63144 applied to be registered as an
importer of the Schedule II control substance for Morphine (9300) the
basic class of controlled substance.
The company plans to import the listed controlled substance in
finished dosage form for internal analytical purposes only. No other
activity for this drug code is authorized for this registration.
Approval of permit applications will occur only when the registrant's
business activity is consistent with what is authorized under 21 U.S.C.
952(a)(2). Authorization will not extend to the import of FDA approved
or non-approved finished dosage forms for commercial sale.
Dated: January 31, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.
[FR Doc. 2018-02647 Filed 2-8-18; 8:45 am]
BILLING CODE 4410-09-P
